Known targets — ChEMBL curated mechanism
ADRB1CDK4CDK6CHRM2CHRM3DPP4DRD2DRD3DRD4EGFRHRH1HTR1BHTR1DHTR1FHTR2AHTR2CHTR4SLC6A2SLC6A4
The experimentally established mechanism targets of Phthalic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.64 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.64 |
| ▸ | HPGD | P15428 | 3/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.53 |
| ▸ | CA12 | O43570 | 3/20 | 0.50 |
| ▸ | CA1 | P00915 | 3/20 | 0.50 |
| ▸ | CA2 | P00918 | 3/20 | 0.50 |
| ▸ | CA4 | P22748 | 3/20 | 0.50 |
| ▸ | CA7 | P43166 | 3/20 | 0.50 |
| ▸ | CA9 | Q16790 | 3/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.50 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | HMGB1 | P09429 | 2/20 | 0.48 |
| ▸ | NAPRT | Q6XQN6 | 2/20 | 0.48 |
| ▸ | ESR1 | P03372 | 1/20 | 0.48 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.48 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phthalic Acid SCHEMBL22217134 | 0.93 | ALDH1A1 (0.74) | ALDH1A1ALOX15HPGDHSD17B10CA12 | |
| Phthalic Acid SCHEMBL125858 | 0.93 | ALDH1A1 (0.74) | ALDH1A1ALOX15HPGDHSD17B10CA12 | |
| Phthalic Acid SCHEMBL27933615 | 0.91 | ALDH1A1 (0.70) | ALDH1A1ALOX15HPGDHSD17B10CA12 | |
| Phthalic Acid SCHEMBL409472 | 0.90 | ALDH1A1 (0.56) | ALDH1A1ALOX15HPGDHSD17B10CA12 | |
| Phthalic Acid SCHEMBL11319635 | 0.89 | ALDH1A1 (0.50) | ALDH1A1ALOX15HPGDHSD17B10CA12 | |
| Phthalic Acid SCHEMBL10624089 | 0.88 | ALDH1A1 (0.67) | ALDH1A1ALOX15HPGDHSD17B10CA12 | |
| Phthalic Acid SCHEMBL2561870 | 0.88 | ALDH1A1 (0.82) | ALDH1A1ALOX15HPGDHSD17B10CA12 | |
| Phthalic Acid SCHEMBL8398555 | 0.88 | ALDH1A1 (0.82) | ALDH1A1ALOX15HPGDHSD17B10CA12 | |
| Phthalic Acid SCHEMBL7897915 | 0.88 | ALDH1A1 (0.82) | ALDH1A1ALOX15HPGDHSD17B10CA12 | |
| Phthalic Acid SCHEMBL30100313 | 0.88 | ALDH1A1 (0.82) | ALDH1A1ALOX15HPGDHSD17B10CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 513 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024119044-A2 | ADRULIPASE COMPOSITIONS | First Wave BioPharma, Inc. (US) | 2024-06-06 | — | — | WO | claimed |
| CN-116437947-A | Non-pig formulations and methods thereof | 第一浪潮生物制药有限公司 | 2023-07-14 | — | — | CN | claimed |
| WO-2023114390-A2 | LIPASE FORMULATIONS AND METHODS THEREOF | First Wave BioPharma, Inc. (US) | 2023-06-22 | — | — | WO | claimed |
| EP-4167970-A1 | NON-PORCINE FORMULATIONS AND METHODS THEREOF | First Wave Biopharma, Inc. (US) | 2023-04-26 | — | — | EP | claimed |
| US-20230075876-A1 | PHARMACEUTICAL COMPOSITION CONTAINING REGORAFENIB AND A STABILIZING AGENT | BAYER AKTIENGESELLSCHAFT (DE) | 2023-03-09 | — | — | US | claimed |
| EP-4099990-A1 | PHARMACEUTICAL COMPOSITION CONTAINING REGORAFENIB AND A STABILIZING AGENT | Bayer Aktiengesellschaft (DE) | 2022-12-14 | — | — | EP | claimed |
| EP-3972569-A1 | NANOPARTICLES COMPRISING ENZALUTAMIDE | Helm AG (DE) | 2022-03-30 | — | — | EP | claimed |
| WO-2021257843-A1 | NON-PORCINE FORMULATIONS AND METHODS THEREOF | AZURRX BIOPHARMA, INC. (US) | 2021-12-23 | — | — | WO | claimed |
| WO-2021156172-A1 | PHARMACEUTICAL COMPOSITION CONTAINING REGORAFENIB AND A STABILIZING AGENT | BAYER AKTIENGESELLSCHAFT (DE) | 2021-08-12 | — | — | WO | claimed |
| EP-3861989-A1 | PHARMACEUTICAL COMPOSITION CONTAINING REGORAFENIB AND A STABILIZING AGENT | Bayer Aktiengesellschaft (DE) | 2021-08-11 | — | — | EP | claimed |
| EP-1263433-A2 | GLYCOGEN PHOSPHORYLASE INHIBITOR | Pfizer Products Inc. (US) | 2002-12-11 | — | — | EP | claimed |
| EP-1239835-A1 | PHARMACEUTICAL COMPOSITIONS PROVIDING ENHANCED DRUG CONCENTRATIONS | Pfizer Products Inc. (US) | 2002-09-18 | — | — | EP | claimed |
| US-20020103225-A1 | Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors | BEND RESEARCH INC. | 2002-08-01 | — | — | US | claimed |
| US-20020006443-A1 | Drug in a solubility-improved form with a concentration-enhancing polymer such as hydroxypropyl methyl cellulose acetate succinate; combination improves bioavailability relative to a control of just solubility improved form | BEND RESEARCH, INC. | 2002-01-17 | — | — | US | claimed |
| US-20010053778-A1 | Pharmaceutical compositions of glycogen phosphorylase inhibitors | BEND RESEARCH, INC. | 2001-12-20 | — | — | US | claimed |
| US-20010053791-A1 | Glycogen phosphorylase inhibitor | BEND RESEARCH, INC. | 2001-12-20 | — | — | US | claimed |
| WO-2001068055-A1 | PHARMACEUTICAL COMPOSITIONS OF GLYCOGEN PHOSPHORYLASE INHIBITORS | PFIZER PRODUCTS INC. (US) | 2001-09-20 | — | — | WO | claimed |
| WO-2001068092-A2 | GLYCOGEN PHOSPHORYLASE INHIBITOR | PFIZER PRODUCTS INC. (US) | 2001-09-20 | — | — | WO | claimed |
| WO-2001047495-A1 | PHARMACEUTICAL COMPOSITIONS PROVIDING ENHANCED DRUG CONCENTRATIONS | PFIZER PRODUCTS INC. (US) | 2001-07-05 | — | — | WO | claimed |
| EP-1027886-A2 | Pharmaceutical solid dispersions | Pfizer Products Inc. (US) | 2000-08-16 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230075876-A1 | PHARMACEUTICAL COMPOSITION CONTAINING REGORAFENIB AND A STABILIZING AGENT | KRAS, NRAS, APC | ALDH1A1 1228/4885ALOX15 3460/4885HPGD 1455/4885 |
| US-20020103225-A1 | Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors | CETP, HDLBP, NPC1L1 | ALDH1A1 4028/4885ALOX15 3584/4885HPGD 3772/4885 |
| US-20010053791-A1 | Glycogen phosphorylase inhibitor | PYGL, PYGM, GYS2 | ALDH1A1 2541/4885ALOX15 3636/4885HPGD 819/4885 |
| US-20010053778-A1 | Pharmaceutical compositions of glycogen phosphorylase inhibitors | PYGL, PYGM, GYS2 | ALDH1A1 3063/4885ALOX15 4024/4885HPGD 1084/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.